ULTIMATE-DAPT study shows that stopping aspirin one month after coronary stenting, followed by ticagrelor monotherapy, reduces bleeding complications without increasing heart attack risk in high-risk patients.
The ULTIMATE-DAPT study shows that stopping aspirin one month after a coronary stenting procedure in high-risk heart patients, and continuing ticagrelor monotherapy for the remaining 11 months, significantly reduces bleeding complications compared to patients on dual antiplatelet therapy (DAPT). The study analyzed 3,400 patients and found no increased risk of heart attacks or other ischemic complications, potentially changing worldwide standard of care guidelines.
April 07, 2024
5 Articles